We are live on ! Find out more
RDHL

Redhill Biopharma
RDHL

17 hedge funds and large institutions have $449K invested in Redhill Biopharma in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

0% more funds holding

Funds holding: 17 → 17 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

43% less capital invested

Capital invested by funds: $782K → $449K (-$333K)

Holders
17
Holders Change
–
Holders Change %
0%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
2
Closed
5
Calls
$24K
Puts
–
Net Calls
+$24K
Net Calls Change
+$15K

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$70.8K
2
FDCDDQ
Federation des caisses Desjardins du Quebec
Quebec, Canada
+$52.1K
3
GS
Gagnon Securities
New York
+$34K
4
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$26K
5
Squarepoint
Squarepoint
New York
+$8.94K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$369K
2
SM
Sabby Management
Florida
-$324K
3
Citadel Advisors
Citadel Advisors
Florida
-$28.4K
4
TSS
Two Sigma Securities
New York
-$12.9K
5
VF
Virtu Financial
New York
-$10K

RDHL Hedge Fund Activity: Q4 2023 in Review

17 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q4 2023, worth a combined $449K — down 43% from $782K a quarter earlier.

Fund positioning in RDHL was balanced in Q4 2023: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 2 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $70.8K. The largest seller was Armistice Capital, exiting entirely with an estimated $369K sold.

  • 17 institutional investors held Redhill Biopharma (RDHL) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $449K of Redhill Biopharma stock for Q4 2023, down 43% quarter-over-quarter.
  • 5 funds opened new Redhill Biopharma positions in Q4 2023 and 5 closed out, a net change of 0 holders.
  • The largest Redhill Biopharma buyer in Q4 2023 was Jane Street, an estimated $70.8K added.
  • The largest Redhill Biopharma seller in Q4 2023 was Armistice Capital, an estimated $369K sold.

Based on aggregated 13F filings for Q4 2023.